Business Context and Reporting Period
This Form 8-K is a current report filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on January 2, 2020. The report details corporate actions taken on December 31, 2019, specifically a reverse stock split intended to regain compliance with Nasdaq Capital Market listing requirements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company effected a one-for-eight (1:8) reverse stock split of its common stock and warrants.
- Share Count Reduction: Outstanding common shares were reduced from approximately 125.1 million to 15.6 million.
- Warrant Count Reduction: Outstanding warrants were reduced from approximately 61.4 million to 7.7 million.
- Trading Details: Trading on a split-adjusted basis commenced on January 6, 2020. The trading symbols remained "EYES" and "EYESW," but CUSIP numbers were updated to 81362J209 (Common Stock) and 81362J126 (Warrants).
- Fractional Shares: No fractional shares or warrants were issued; holders received cash payments for fractional interests based on the volume-weighted average trading price of the five trading days preceding the effective date.
Guidance, Outlook, and Risks
Management Commentary: The reverse split was approved by majority stockholders on November 26, 2019, to satisfy the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include the Company's ability to attain and maintain the necessary stock price levels to comply with Nasdaq's continued listing standards. Future compliance depends on the Company's financial condition, results of operations, and market perception.
Investor Verification Checklist
- Verify the new CUSIP numbers (81362J209 for stock, 81362J126 for warrants) with your broker to ensure proper account updates.
- Confirm receipt of cash payments for any fractional shares or warrants held prior to the split.
- Monitor the stock price post-split to ensure it remains above the $1.00 minimum bid price required for continued Nasdaq listing.
- Review the Second Amendment to Restated Articles of Incorporation (Exhibit 3.1) for specific legal terms regarding the split.